| OSRX® Bimatoprost + Dorzolamide + Timolol | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dosing | qpm | ||||||||||
| Chem Specs | bimatoprost 0.01% , dorzolamide 2.0%, timolol 0.5% | ||||||||||
| Quantities | 5ml, | ||||||||||
| Cost | 25.00 | ||||||||||
| Class | bimatoprost: Prostaglandin analog. dorzolamide : Carbonic anhydrase inhibitor timolol: Non-selective beta-adrenergic receptor blocker. | ||||||||||
| Usage | Single container preparation reduces cost and enhances compliance.
| Contraindications |
| bimatoprost Hypersensitivity to bimatoprost or other included ingredients. dorzolamide Sulfonamide hypersensitivity.
timolol Bronchial asthma, a history of bronchial asthma, COPD, sinus bradycardia,
second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. Numerous additional cautions listed here. Pediatric use |
Not recommended below the age of 16 due to potential increased pigmentation with chronic use.
|
Pregnancy |
There are no adequate studies in pregnant women for these ingredients. Teratogenicity shown in |
rabbits at 37x the human dose but not at 16x. Caution |
Bimatorost: lid, lash and iris pigmentation increases with chronic use. Iris pigentation remains |
after discontinuation.
| Compounded in OSRX 503A/503B approved pharmacy. BAK preserved.
|
|